...
首页> 外文期刊>Microcirculation: The official journal of the Microcirculatory Society >Oxidized low-density lipoprotein inhibits nitric oxide-mediated coronary arteriolar dilation by up-regulating endothelial arginase I.
【24h】

Oxidized low-density lipoprotein inhibits nitric oxide-mediated coronary arteriolar dilation by up-regulating endothelial arginase I.

机译:氧化的低密度脂蛋白通过上调内皮精氨酸酶I抑制一氧化氮介导的冠状动脉扩张。

获取原文
获取原文并翻译 | 示例

摘要

Oxidized low-density lipoprotein (OxLDL) causes impairment of endothelium-dependent, nitric oxide (NO)-mediated vasodilation involving l-arginine deficiency. However, the underlying mechanism remains elusive. Since arginase and endothelial NO synthase (eNOS) share the substrate l-arginine, we hypothesized that OxLDL may reduce l-arginine availability to eNOS for NO production, and thus vasodilation, by up-regulating arginase. To test this hypothesis, porcine subepicardial arterioles (70-130 mum) were isolated for vasomotor study and for immunohistochemical detection of arginase and eNOS expressions. The coronary arterioles dilated dose-dependently to the endothelium-dependent NO-mediated vasodilator serotonin. This vasodilation was inhibited in the same manner by NOS inhibitor N(G)-nitro-l-arginine methyl ester and by lumenal OxLDL (0.5 mg protein/mL). The inhibitory effect of OxLDL was reversed after treating the vessels with either l-arginine (3 mM) or arginase inhibitor difluoromethylornithine (DFMO; 0.4 mM). Consistent with vasomotor alterations, OxLDL inhibited serotonin-induced NO release from coronary arterioles and this inhibition was reversed by DFMO. Vascular arginase activity was significantly elevated by OxLDL. Immunohistochemical analysis indicated that OxLDL increased arginase I expression in the vascular wall without altering eNOS expression. Taken together, these results suggest that OxLDL up-regulates arginase I, which contributes to endothelial dysfunction by reducing l-arginine availability to eNOS for NO production and thus vasodilation.
机译:氧化的低密度脂蛋白(OxLDL)导致内皮依赖性,一氧化氮(NO)介导的血管舒张功能受损,涉及l-精氨酸缺乏。但是,基本机制仍然难以捉摸。由于精氨酸酶和内皮一氧化氮合酶(eNOS)共享底物l-精氨酸,我们假设OxLDL可通过上调精氨酸酶来降低eNOS产生l-精氨酸对eNOS的利用率,从而减少血管舒张。为了验证该假设,分离了猪心外膜下小动脉(70-130毫米)用于血管舒缩研究以及用于精氨酸酶和eNOS表达的免疫组化检测。冠状小动脉剂量依赖性地扩展至内皮依赖性NO介导的血管扩张剂5-羟色胺。这种血管舒张作用以同样的方式被NOS抑制剂N(G)-硝基-1-精氨酸甲酯和腔内OxLDL(0.5 mg蛋白/ mL)抑制。用L-精氨酸(3 mM)或精氨酸酶抑制剂二氟甲基鸟氨酸(DFMO; 0.4 mM)处理血管后,OxLDL的抑制作用被逆转。与血管舒缩改变相一致,OxLDL抑制了血清素诱导的NO从冠状小动脉的释放,这种抑制作用被DFMO逆转。 OxLDL显着提高了血管精氨酸酶的活性。免疫组织化学分析表明,OxLDL增加了血管壁中精氨酸酶I的表达,而没有改变eNOS的表达。两者合计,这些结果表明,OxLDL上调精氨酸酶I,这通过减少eNOS的l-精氨酸对NO的产生和血管舒张的可用性而导致内皮功能障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号